Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Tax Provisions (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Tax Provisions for 9 consecutive years, with $870000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 37.14% to $870000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 33.33% year-over-year, with the annual reading at $4.0 million for FY2025, 33.33% up from the prior year.
  • Tax Provisions for Q4 2025 was $870000.0 at Ultragenyx Pharmaceutical, roughly flat from $873000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $6.3 million in Q3 2022, with the low at -$3.9 million in Q4 2023.
  • Average Tax Provisions over 5 years is $669000.0, with a median of $526500.0 recorded in 2022.
  • The sharpest move saw Tax Provisions surged 3354.4% in 2022, then plummeted 2151.32% in 2023.
  • Over 5 years, Tax Provisions stood at $20000.0 in 2021, then skyrocketed by 845.0% to $189000.0 in 2022, then tumbled by 2151.32% to -$3.9 million in 2023, then surged by 135.7% to $1.4 million in 2024, then crashed by 37.14% to $870000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $870000.0, $873000.0, and $947000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.